Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

PAR-21-306: NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)

Closed Closed October 31, 2023 Opportunity PAR-21-306

This grant is closed. A newer notice from the same program is open now: NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) (PAR-28-063). Status: Due dates in the notice, expires February 20, 2029. It is in our archive of National Institutes of Health notices from 2021.

National Institutes of Health offered grants to colleges and universities, state and local governments and tribes. Applications closed on October 31, 2023.

From the official notice on Grants.gov, last changed October 16, 2023. Checked November 7, 2026.

About this NIH notice

Projects funded under PAR-21-306 were run by National Cancer Institute (NCI, 38 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.

Application due dates, page limits and budget limits are set in the notice. Read PAR-21-306 in the NIH Guide.

Other notices with this title

National Institutes of Health has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
PAR-28-063November 3, 2026Due dates in the notice, expires February 20, 2029Open
PAR-24-274August 22, 2024Closed November 4, 2025Closed

Key dates

PostedAugust 20, 2021
DeadlineOctober 31, 2023
Archived by Grants.govNovember 30, 2023

Who can apply

This opportunity was open to colleges and universities, state and local governments and tribes.

All 11 applicant types the notice lists

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

More grants for colleges and universities, state and local governments, tribes.

Is this a realistic fit?

What the grant funds

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants. These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award (R50) is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of support for career continuity.

Category: Education, Health.

Funded under PAR-21-306 so far

NIH funded 38 projects under PAR-21-306 in fiscal 2023 to 2026, at 32 institutions. The median yearly award was $151,957.

Most projects: Johns Hopkins University (Maryland), 3, University of Kansas Medical Center (Kansas), 2, University of TX MD Anderson Can Ctr (Texas), 2, Emory University (Georgia), 2, Mayo Clinic Rochester (Minnesota), 2.

From NIH RePORTER, which lists each project once per fiscal year it was funded. Amounts are the yearly award.

Who has won Cancer Treatment Research grants before

From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Univeristy of Texas M.D. Anderson Cancer CenterTexas144$188 million
Dana-Farber Cancer Institute, Inc.Massachusetts68$185 million
Icahn School of Medicine at Mount SinaiNew York35$179 million
Public Health InstituteCalifornia4$168 million
Fred Hutchinson Cancer CenterWashington57$156 million

Top states: California ($843 million), New York ($604 million), Massachusetts ($568 million), Texas ($444 million), Pennsylvania ($417 million).

Who has won Cancer Biology Research grants before

From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Trustees of Columbia University in the City of New YorkNew York70$151 million
The Univeristy of Texas M.D. Anderson Cancer CenterTexas109$144 million
Sloan-Kettering Institute for Cancer ResearchNew York66$136 million
Dana-Farber Cancer Institute, Inc.Massachusetts47$107 million
The Regents of the University of California, San FranciscoCalifornia64$95.5 million

Top states: New York ($712 million), California ($608 million), Massachusetts ($409 million), Texas ($373 million), Pennsylvania ($286 million).

Who has won Cancer Cause and Prevention Research grants before

From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Univeristy of Texas M.D. Anderson Cancer CenterTexas81$107 million
Sloan-Kettering Institute for Cancer ResearchNew York65$99.1 million
The Trustees of Columbia University in the City of New YorkNew York48$85.3 million
Dana-Farber Cancer Institute, Inc.Massachusetts51$83.1 million
University of North Carolina at Chapel HillNorth Carolina49$76.1 million

Top states: California ($465 million), New York ($445 million), Massachusetts ($350 million), Texas ($259 million), Pennsylvania ($175 million).

Other programs behind this notice

Applying now

This notice no longer takes applications. Apply under the newer notice, PAR-28-063, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is PAR-21-306 still open?

No. It closed on October 31, 2023. A newer notice is open: PAR-28-063, due dates in the notice, expires February 20, 2029.

Who can apply for NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from colleges and universities, state and local governments and tribes. The notice adds further conditions, so read its eligibility section.

What is the deadline for NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)?

Closed October 31, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

Who has been funded under PAR-21-306?

NIH RePORTER lists 38 projects funded under PAR-21-306 in fiscal 2023 to 2026, at 32 institutions. The most were at Johns Hopkins University, University of Kansas Medical Center, University of TX MD Anderson Can Ctr.

Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.

Similar open grants